受强制性开放获取政策约束的文章 - Matteo Duca了解详情
无法在其他位置公开访问的文章：1 篇
A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody–Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors
M Duca, DWT Lim, V Subbiah, S Takahashi, J Sarantopoulos, A Varga, ...
Molecular cancer therapeutics 21 (4), 625-634, 2022
强制性开放获取政策： US National Institutes of Health
可在其他位置公开访问的文章：4 篇
Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)
A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ...
Cancer discovery 7 (4), 400-409, 2017
强制性开放获取政策： US National Institutes of Health
Molecular tumor board as a clinical tool for converting molecular data into real-world patient care
A Vingiani, L Agnelli, M Duca, D Lorenzini, S Damian, C Proto, M Niger, ...
JCO Precision Oncology 7, e2300067, 2023
强制性开放获取政策： Government of Italy
Ascites during selpercatinib treatment: need for a multidisciplinary approach
L Provenzano, S Damian, M Duca, S Della Valle, FGM De Braud
Journal of Thoracic Oncology 18 (2), e9-e10, 2023
强制性开放获取政策： US National Institutes of Health, US Department of Veterans Affairs
PROACT 2.0: A new open-source tool to improve patient-doctor communication in clinical trials
L Agnelli, A Villa, F Butt, M Duca, A Guidi, M Carapezza, M Addante, ...
Tumori Journal, 03008916241248007, 2024
强制性开放获取政策： Cancer Research UK, National Institute for Health Research, UK
出版信息和资助信息由计算机程序自动确定